Optimal use of bisphosphonates in patients with multiple myeloma

Blood

Volumn 121, Issue 17, 2013, Pages 3325-3328

  Terpos, Evangelos ^a   Roodman, G David ^b   Dimopoulos, Meletios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CREATININE; M PROTEIN; BONE DENSITY CONSERVATION AGENT;

ACUTE PHASE RESPONSE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DISEASE; BONE MARROW BIOPSY; CASE REPORT; CELL INFILTRATION; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAW OSTEONECROSIS; KIDNEY DISEASE; LOW BACK PAIN; LUMBAR SPINE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMA CELL; PRIORITY JOURNAL; SPINE FRACTURE; TREATMENT DURATION; PROGNOSIS; REVIEW;

BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; DIPHOSPHONATES; HUMANS; MULTIPLE MYELOMA; PROGNOSIS;

MLCS; MLOWN;

EID: 84879357838     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-435750     Document Type: Article

References (20)

1. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol. 2005;16(8): 1223-1231.
2. Dimopoulos M, Terpos E, Comenzo RL, et al; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23(9):1545-1556.
3. Terpos E, Moulopoulos LA, Dimopoulos MA. Advances in imaging and the management of myeloma bone disease. J Clin Oncol. 2011; 29(14):1907-1915.
4. McCloskey EV, MacLennan IC, Drayson MT, et al; MRC Working Party on Leukaemia in Adults. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol. 1998;100(2): 317-325.
5. Berenson JR, Lichtenstein A, Porter L, et al; Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334(8): 488-493.
6. Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91(7):1191-1200.
7. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98(8):1735-1744.
8. Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11(10): 973-982.
9. Morgan GJ, Davies FE, Gregory WM, et al; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999.
10. Morgan GJ, Child JA, Gregory WM, et al; National Cancer Research Institute Haematological Oncology Clinical Studies Group. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12(8):743-752.
11. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev. 2012;5:CD003188.
12. D’Arena G, Gobbi PG, Broglia C, et al; Gimema (Gruppo Italiano Malattie Ematologiche Dell’Adulto); Multiple Myeloma Working Party; Gisl (Gruppo Italiano Studio Linfomi) Cooperative Group. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study. Leuk Lymphoma. 2011;52(5):771-775.
13. Musto P, Petrucci MT, Bringhen S, et al; GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113(7): 1588-1595.
14. Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood. 2012;119(23):5374-5383.
15. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28(33):4976-4984.
16. Berenson JR, Rosen L, Vescio R, et al. Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol. 1997;37(4):285-290.
17. Saha H, Castren-Kortekangas P, Ojanen S, et al. Pharmacokinetics of clodronate in renal failure. J Bone Miner Res. 1994;9(12): 1953-1958.
18. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91(7): 968-971.
19. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20(1): 117-120.
20. Hellstein JW, Adler RA, Edwards B, et al; American Dental Association Council on Scientific Affairs Expert Panel on Antiresorptive Agents. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011; 142(11):1243-1251.